Pulmonary contraindications, indications and MELD exceptions for liver transplantation: A contemporary view and look forward  Michael J. Krowka, Russell H. Wiesner, Julie K. Heimbach  Journal of Hepatology  Volume 59, Issue 2, Pages 367-374 (August 2013) DOI: 10.1016/j.jhep.2013.03.026 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 1 Long-term outcome following liver transplantation in patients with hepatopulmonary syndrome based upon their baseline PaO2 at the time of diagnosis pre-transplant. No difference was observed between the PaO2 cut-offs. Adapted from [12], reprinted with permission. Journal of Hepatology 2013 59, 367-374DOI: (10.1016/j.jhep.2013.03.026) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Five-year survival in patients with portopulmonary hypertension compared to those with idiopathic pulmonary artery hypertension. Uncontrolled treatments in both groups. None with POPH underwent liver transplant. aOnly patients enrolled within 5years of diagnosis were included in the 5-year survival from diagnosis curve. Adapted from [16], reprinted with permission. Journal of Hepatology 2013 59, 367-374DOI: (10.1016/j.jhep.2013.03.026) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 3 Pre and post-transplant CXR in HHT patient with high-output cardiac failure. (A) Pre-transplant embolization of pulmonary arteriovenous malformation in the left lower lobe was observed. (B) At 24months post liver transplant, pulmonary venous hypertension and cardiac failure resolved, but cardiomegaly was still present. Journal of Hepatology 2013 59, 367-374DOI: (10.1016/j.jhep.2013.03.026) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Fig. 4 Resolution of severe HPS (standing PaO2 mmHg: 46 on room air, 106 on 100% inspired oxygen) with liver transplant; followed by progression idiopathic pulmonary fibrosis and subsequent lung single transplant. (A) Pre-liver transplant cxr; (B) 14month post-liver transplant cxr showing IPF progression (PaO2); (C) 20month post-lung transplant cxr. Journal of Hepatology 2013 59, 367-374DOI: (10.1016/j.jhep.2013.03.026) Copyright © 2013 European Association for the Study of the Liver Terms and Conditions

Journal of Hepatology 2013 59, 367-374DOI: (10. 1016/j. jhep. 2013. 03 Copyright © 2013 European Association for the Study of the Liver Terms and Conditions